BioElectronics Corporation Announces Substantial Increase in 4th Quarter 2020 Revenue; Major Convertible Debt Holders Agree to Forego Interest in 2021

BIEL +23.33%  Frederick, Maryland, Jan. 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (OTC PINK:BIEL) is pleased to report that Q4 revenue for 2020 exceeded $519,000, representing an increase of 241% when compared to Q3 revenue in 2020 ($151,956). Correspondingly, Q4 2020 revenue represents an increase of 233% when compared to the cumulative revenue of … Continue Reading

BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market

BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market FREDERICK, MD, Dec. 15, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (OTC PINK: BIEL), ( is pleased to announce that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce … Continue Reading

BioElectronics’ ActiPatch® Therapy To Be Marketed By DonJoy® Advantage

Drug-Free Pain Relief Technology with Premium Wraps FREDERICK, Md.,  Nov. 6, 2020 /PRNewswire/ — BioElectronics Corporation (OTC PINK: BIEL),  www.bielcorp.comis pleased to announce the execution of a commercial partnership agreement with Scott Specialties Inc (SS to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy® (DJO Advantage product line. This commercial … Continue Reading

Richard Staelin, Ph.D. Rejoins the Board of BioElectronics Corporation

FREDERICK, MD, June 15, 2020 (GLOBE NEWSWIRE) —  via NEWMEDIAWIRE – BioElectronics Corporation (OTC: BIEL),, the maker of non-invasive electroceutical devices, announced today that it has appointed Richard Staelin, Ph.D. as the Chairman of the Board following the resignation and retirement of Ms. Patricia Whelan.  “The management team at BioElectronics thanks Patricia Whelan for her … Continue Reading

BioElectronics Announces FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain

FREDERICK, MD- February 3, 2020 – BioElectronics Corporation (OTC PINK: BIEL),, the maker of non-invasive electroceutical devices, is pleased to announce that it has obtained a new 510(k) clearance from the U.S. Food and Drug Administration (FDA).  This new, over-the counter marketing clearance was granted for the drug free ActiPatch® medical device, for the … Continue Reading

BioElectronics ActiPatch Drug Free Pain Therapy Receives United Kingdom National Health System Payment Coverage

FREDERICK, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half … Continue Reading

BioElectronics Announces Drug Free Solution to the Opioid Crisis (ActiPatch)

FREDERICK, MD–(Marketwired – Nov 6, 2017) – BioElectronics Corporation ( OTC PINK :BIEL ), the maker of advanced consumer pain management medical device, ActiPatch, today announced that it has taken on the responsibility to find a DRUG-FREE solution to the Opioid Crisis. The reach of the opioid crisis now stretches wide and far, claiming an American life every … Continue Reading

BioElectronics Announces Independent Back Pain Clinical Study Pulsed Neuromodulation Therapy (ActiPatch) for Chronic Musculoskeletal Lower Back Pain

FREDERICK, MD–(Marketwired – Oct 16, 2017) – BioElectronics Corporation ( OTC PINK : BIEL ), is pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic musculoskeletal lower back pain. Low back pain is highly prevalent and affects 1 in 3 adult Americans, accounting for about $ 90 billion in direct spending every … Continue Reading

BioElectronics Completes Subject Enrollment for Migraine Clinical Study; Migraine Prevention Using ActiPatch (Neuromodulation Therapy)

FREDERICK, MD–(Marketwired – Sep 25, 2017) –  BioElectronics Corporation ( OTC PINK : BIEL ), is pleased to report on the progress of its Migraine prevention clinical study. The randomized, double-blinded, sham-controlled study involving 48 subjects is designed to investigate if ActiPatch therapy can be used to prevent the frequency and intensity of migraine attacks. Since receiving IRB-approval for the … Continue Reading